Diagnostic and Prognostic Biomarkers of Sepsis

Overview

This study aims to evaluate sepsis biomarkers as soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) and soluble urokinase plasminogen activator receptor (sUPAR) in diagnosis of sepsis in comparison to the traditional blood culture and C-reactive protein (CRP) and to evaluate the prognostic value of these biomarkers in comparison to sequential organ failure assessment score (SOFA score), Acute Physiology and Chronic Health Evaluation II ( APACHI score), 28 day mortality.

Full Title of Study: “Evaluation of the Role of sTREM-1 and sUPAR Biomarkers as a Diagnostic Tool and Prognostic Predictor in Sepsis Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 1, 2020

Detailed Description

Sepsis is usually diagnosed in patients have clinically suspected infections with systemic inflammatory response syndrome (SIRS) manifestations. Patients with SIRS as those with trauma or stroke have the same classic infection signs such as fever and elevated leukocytic count, as long as the microbiological diagnosis is the ultimate diagnostic method, but it has poor sensitivity with delayed results. New biomarkers such as sTREM-1 and sUPAR can be used for rapid diagnosis of sepsis and differentiating it from non infectious inflammatory syndromes. Also these soluble biomarkers can be used for predicting the prognosis of sepsis patients

Clinical Trial Outcome Measures

Primary Measures

  • Measurement of the serum level of sTREM-1 (ng/L) in the patients with criteria of SIRS
    • Time Frame: in the 1st day after appearance of clinical signs of infection
    • by ELISA”enzyme linked immunosorbent assay”
  • Measurement of the serum level of sTREM-1 (ng/L) in the patients with criteria of SIRS
    • Time Frame: in the 7th day after appearance of clinical signs of infection
    • by ELISA”enzyme linked immunosorbent assay”
  • Measurement of the serum level of sUPAR (ng/L) in the ICU patients
    • Time Frame: in the 1st day after appearance of clinical signs of infection
    • by ELISA”enzyme linked immunosorbent assay”
  • Measurement of the serum level of sUPAR (ng/L) in the patients with criteria of SIRS
    • Time Frame: in the 7th day after appearance of clinical signs of infection
    • by ELISA”enzyme linked immunosorbent assay”
  • Measurement of the serum level of CRP (mg/dl) in the patients with criteria of SIRS
    • Time Frame: in the 1st day after appearance of clinical signs of infection
    • by turbidimetry
  • Measurement of the serum level of CRP (mg/dl) in the patients with criteria of SIRS
    • Time Frame: in the 7th day after appearance of clinical signs of infection
    • by turbidimetry

Secondary Measures

  • Acute Physiology and Chronic Health Evaluation II (APACHE II) score designed to measure the severity of disease for adult patients admitted to intensive care units in the with criteria of SIRS
    • Time Frame: in the 7th day after appearance of clinical signs of infection
    • an integer score from 0 to 71
  • The sequential organ failure assessment score (SOFA score) had been used to determine the extent of organ dysfunction of ICU patients with criteria of SIRS
    • Time Frame: in the 7th day after appearance of clinical signs of infection
    • 0-<11

Participating in This Clinical Trial

Inclusion Criteria

  • Temperature of >38oC – Heart rate of >90 beats/min – Respiratory rate of >20 breaths/min – Partial pressure of arterial carbon dioxide (PaCO2) of <32 mmHg – White blood cell (WBC) count of >12,000 cells/mm3 Exclusion Criteria:

  • HIV patients – Patients with neutropenia <1000 cells/mm3 – <18 years of age.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: 70 Years

Investigator Details

  • Lead Sponsor
    • Sohag University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nahed Fathallah Fahmy, lecturer of medical microbiology & immunology departement -faculty of medicine – Sohag University
  • Overall Official(s)
    • Nahed Fathallah, lecturer, Principal Investigator, Sohag University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.